- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01919021
Assessment of Gastro-Intestinal Function to a Mixed Meal by Non-invasive Imaging
Pilot Study: Assessment of Gastric Motor and Sensory Function to a Mixed Liquid and Solid Test Meal by Gamma Scintigraphy, Magnetic Resonance Imaging and a Nutrient Drink Test in Health and Patients With Disorders of Gastric Function
Dyspeptic symptoms, such as pain after eating, bloating and nausea all have major impact on quality of life and health care costs. When no structural cause is identified, patients are diagnosed with functional dyspepsia. This trial aims to identify objective abnormalities of stomach function that explain patient's symptoms and establish diagnosis. Another group are diabetic patients who can often develop similar symptoms, labelled as diabetic gastroparesis. In some cases this is associated with delayed gastric emptying but not all.
24 patients with functional dyspepsia will be studied and 24 healthy controls (to establish normal ranges) and 24 diabetic patients with symptoms of functional dyspepsia.
The utility of 3 different non-invasive investigations will be assessed. At screening the nutrient drink test (NDT) asks the patient to drink 40ml of milkshake (0.75kcal/ml) every minute and score symptoms every 5 minutes. The patient continues until they reach the maximum tolerated volume.
Participants will then be randomized to undergo non-invasive imaging on two separate test days by magnetic resonance imaging (MRI) and gastric scintigraphy MRI will be completed with the patient ingesting 400ml of milkshake (identical to NDT) and 12 agar beads (no additional calories) of known breaking strength. The emptying of the stomach will be visualised with the MRI alongside symptom recording.
Gamma scintigraphy will ingest the same meal as for the MRI scan but radioactive labelling will allow the rate of liquid and solid meal emptying to be visualised alongside symptom recording.
Additionally, blood sugars will be recorded before nutrient drink test and at 15 and 30 minutes following ingestion of 400ml of milkshake and 12 agar beads.
Data will be analyzed to assess the association of objective abnormalities of gastric function and patient symptoms. Additionally the results of non-invasive imaging by MRI and GS will be compared to assess the optimal measurement of gastric function and emptying in this clinical scenario.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nottingham, United Kingdom, NG7 2YH
- National Institute of Health Research Biomedical Research Unit, Nottingham Digestve Diseases Centre, University of Nottingham,
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be an adult patient above 18 years old
- Have a body mass index of >18 and <30kg.m2 and not exceed a waist circumference of 99cm at 5cm above ileal crest
- Be able to give voluntary informed consent and from whom written consent to participate has been obtained.
- Be able to understand the study, willing to co-operate with the study procedures and able to attend all study assessments.
- Be willing to abstain from alcohol for 24 hours before and during the imaging appointment.
- Be willing to fast from midnight prior to the screening and imaging appointment
- Be able to ingest at least 400ml nutrient liquid (0.75kcal/ml at 40ml/min) during a Nutrient Drinking Test without experiencing more than moderate dyspeptic symptoms (no such restriction for patients with dyspeptic symptoms)
- Be able to swallow a solid agar bead between 7.5 and 11.5 mm in diameter
- Be willing to consent to their General Practitioner (GP) being informed of their participation.
Exclusion Criteria:
- Have a history of gastrointestinal disease or surgery (other than appendicitis or hysterectomy)
- Have ongoing disease requiring active management (including impaired renal clearance GFR <50 mL/min/1.73 m2)
- Have a documented history of alcohol or drug abuse
- Fail to satisfy the investigator's assessment of fitness to participate based on a survey of inclusion and exclusion criteria
- Have consumed alcohol within 24 hours of start of study
- Have participated in a similar study involving the use of radioisotopes in the previous 3 months such that participating in the current study would exceed the recommended yearly exposure limit (5mSv)
- Take any medication which may affect oesophageal or gastric motility for a minimum 7 days
- Have had previous history of gastric surgery
- Have active upper gastrointestinal diseases
- Have an active Eating Disorder
- Have an allergy to milk protein (milk based, lactose free test meal)
- Be a vegan
- Be pregnant or breastfeeding
- Have any contraindication to MRI scanning according to local guidelines
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum volume ingested at nutrient drink test (ml)
Time Frame: Study Day
|
Maximum of milkshake ingested at maximum satiety
|
Study Day
|
|
Gastric emptying rate (ml/min) for liquids
Time Frame: Study day
|
gastric emptying rate measured by non-invasive imaging
|
Study day
|
|
Gastric emptying rate (ml/min) for solids
Time Frame: Study Day
|
Gastric emptying rate measured by non-invasive imaging
|
Study Day
|
|
Time taken for 50% gastric emptying (T50, minutes) for liquids
Time Frame: Study day-After 50% of contents of stomach has emptied
|
time taken for 50% of gastric contents to leave the stomach
|
Study day-After 50% of contents of stomach has emptied
|
|
Time take for 50% gastric emptying (T50, minutes) solids
Time Frame: Study day-after 50% of contents of stomach has emptied
|
Time taken for 50% of gastric contents to leave the stomach
|
Study day-after 50% of contents of stomach has emptied
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensation at 200ml, 400ml and at completion of nutrient drink test (fullness, bloating, nausea, heartburn, epigastric pain)
Time Frame: Study day
|
Visual analogue score for each sensation (score up to 100 points)
|
Study day
|
|
Glycaemic response at 15 minutes and 30 minutes post 400ml milkshake
Time Frame: study day
|
Blood glucose (mmol/l)
|
study day
|
|
Gastric volume at 200ml nutrient ingestion
Time Frame: Study day
|
Measurement of gastric volume (ml) on MRI and gamma scintigraphy
|
Study day
|
|
Gastric volume at 400ml nutrient ingestion
Time Frame: study day
|
measurement of gastric volume (ml) on MRI and gamma scintography
|
study day
|
|
Gastric contractile wave contractile frequency
Time Frame: study day
|
contractile frequency within stomach
|
study day
|
|
Oro-caecal Transit time
Time Frame: study day
|
Time taken for 50% gastric contents to enter caecum
|
study day
|
|
Sensation threshold volume for fullness, bloating, nausea, heartburn and epigastric pain
Time Frame: study day
|
Gastric volume recorded at time of maximum symptom scores
|
study day
|
|
Sensation at 200ml and 400ml ingestion of test meal (fullness, bloating, nausea, heartburn, epigastric pain)
Time Frame: study day
|
Visual analogue score for each sensation (score up to 100 points)
|
study day
|
|
GI Hormone Assessment
Time Frame: Study day
|
5 ml of blood will be taken at time 0, 30, 60 and 120 min.
GI peptide hormones will then be analysed from the samples.
|
Study day
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Mark Fox, BMBS, MD, University of Nottingham
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11GA006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Dyspepsia
-
Nordic Biotic Sp. z o.o.Not yet recruitingFunctional Dyspepsia
-
BiocodexRecruitingFunctional DyspepsiaFrance
-
Indonesia UniversityRecruitingFunctional DyspepsiaIndonesia
-
Universitaire Ziekenhuizen KU LeuvenNot yet recruitingFunctional DyspepsiaBelgium
-
The Third Affiliated hospital of Zhejiang Chinese...Not yet recruitingFunctional Dyspepsia | ElectroacupunctureChina
-
The Hong Kong Polytechnic UniversityActive, not recruitingPediatric Functional DyspepsiaChina
-
King Chulalongkorn Memorial HospitalRecruiting
-
Wuhan Central HospitalNot yet recruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Hong Kong Baptist UniversityXiyuan Hospital of China Academy of Chinese Medical SciencesRecruitingFunctional DyspepsiaHong Kong
Clinical Trials on Magnetic Resonance Imaging MRI
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
M.D. Anderson Cancer CenterCompletedVaginal CancerUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
University of CincinnatiActive, not recruitingProstate CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Terminated
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedBrain NeoplasmUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedGlioma | Brain MassUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted
-
American College of RadiologyPennsylvania Department of HealthCompleted